Tandem Diabetes Care, Inc. Stock News

MARKHAM, Ontario--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump users can now access full compatibility with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. The t:slim X2 insulin pump with Control-IQ t...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024 at 8:00am Eastern Time (5:00am Pacific Time), and Citi's 2024 Global Healthcare Conferen...

Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales guidance for the year ending December 31, 2024. Third Quarter 2024 Highlights Worldwide GAAP sales increased 31 percent to $244.0 million compared to third quarter 2023;...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: UBS Global Healthcare Conference on Thursday, November 14, 2024 at 11:45am Eastern Time (8:45am Pacific Time), Stifel 2024 Healthcare Conference on...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2024 results after the financial markets close on Wednesday, November 6, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third qu...

Flat revenue growth might be in store for the company in a very crucial market.

It earned a regulatory nod in one of the largest markets in the world. Approval was granted for a system to deliver an ultra-rapid insulin product developed by Eli Lilly.